News Releases | BioAtla, Inc

Date
12/20/24	BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
12/16/24	BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
12/10/24	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
11/7/24	BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
10/31/24	BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
10/4/24	BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
10/1/24	BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
9/23/24	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
9/16/24	BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
9/9/24	BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting